EMBC - NASDAQ
Embecta Corp.
$3.32
-2.8%Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
At a Glance
Live SnapshotEmbecta Corp. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Embecta Corp. Income Statement
EMBC • NASDAQ
| Embecta Corp. Income Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 1.1B | 1.1B | |
GROSS PROFIT | |||||||
(400.9M) | (394.2M) | (370.9M) | (354.6M) | (365M) | (322.9M) | (323M) | |
679.5M | 728.9M | 749.9M | 774.9M | 800M | 762.6M | 786M | |
OPERATING INCOME | |||||||
(350.2M) | (554.7M) | (520.3M) | (396.8M) | (308M) | (276.1M) | (284M) | |
(331.4M) | (365.1M) | (341.3M) | (294.8M) | (240M) | (214.7M) | (222M) | |
(21.5M) | (78.8M) | (85.2M) | (65M) | (63M) | (61.4M) | (62M) | |
329.3M | 174.2M | 229.6M | 378.1M | 492M | 486.5M | 502M | |
PRE-TAX INCOME | |||||||
(107.3M) | (112.3M) | (107M) | (46.2M) | (0.0) | (0.0) | (0.0) | |
-107.3M | -112.3M | -107M | -46.2M | 0.0 | 0.0 | 0.0 | |
-2.7M | (110.8M) | (93.8M) | (37M) | (5M) | (0.0) | (0.0) | |
-193M | -130M | -123.9M | -121.5M | 3M | -700K | -2M | |
136.3M | 44.2M | 105.7M | 256.6M | 495M | 485.8M | 500M | |
NET INCOME | |||||||
(40.9M) | -34.1M | (35.3M) | (33M) | (80M) | (58.2M) | (68M) | |
95.4M | 78.3M | 70.4M | 223.6M | 414.8M | 427.6M | 432M |
SEC Filings
EMBC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 11, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | December 18, 2025 | February 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | November 25, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 25, 2025 | November 25, 2025 | 2025 |
Related Guides
Continue your EMBC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.